RK-33

• GMP format available

RK-33 is a first-in-class small molecule inhibitor of DDX3 (an RNA helicase), with an IC50 value ranging from 4.4 to 8.4 µM for cancer cell lines with high levels of DDX3 expression. This compound is primarily used in cancer research due to its ability to inhibit DDX3 activity, leading to cell cycle arrest, apoptosis, and enhanced radiation sensitivity.

Key features and applications include:

• Selective Inhibition: Specifically targets DDX3, disrupting its helicase activity and impairing Wnt signaling.
• Induces Apoptosis: Promotes programmed cell death in DDX3-overexpressing cancer cells.
• Radiation Sensitizer: Enhances the efficacy of radiation therapy in cancer treatment.
• Combination Therapy: Explored in combination with radiation therapy to improve treatment outcomes.
• Metastasis Studies: Investigates the role of DDX3 in cancer metastasis and its potential as a therapeutic target.

Relevant disease states include:

• Lung Cancer: Demonstrates significant anti-cancer activity and radiosensitization in lung cancer cell lines.
• Breast Cancer: Effective in reducing breast cancer bone metastasis and preventing further cancer spread.
• Colorectal Cancer: Inhibits the growth and proliferation of colorectal cancer cells.

RK-33 is a valuable tool in oncology research, offering insights into the mechanisms of cancer progression and potential therapeutic strategies for various cancers.